Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241EnglishN2023June25Pharmaceutical SciencesNovel Chalcones as Promising Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors     English0103Kamini KashyapEnglishKamini Kashyap, Department of Pharmaceutics, Sanjivani Institute of Pharmacy, Beltukri, Ganiyari, Bilaspur 495001, Chhattisgarh, India.https://doi.org/10.31782/IJMPS.2023.13601The current study focuses on the emerging idea of naturally occuring, chalcone-based inhibitors that will prevent angiogenic switching (fibroblast growth factor angiogenin, TGF-), which is prevented by directly inhibiting vascular endothelial growth factor receptor-2 (VEGFR-2), which prevents neovascularization, vascular formation, and network formation. The presented papers will encourage future researchers, pharmaceutical scientists, aspirant investigators, and related specialists to develop or look at potential angiogenic inhibitors. EnglishAngiogenesis, Cancer, Chalcone, Inhibition, Vascular endothelial growth factor, Vascular Endothelial Growth Factor Receptor-2http://ijcrr.com/abstract.php?article_id=229http://ijcrr.com/article_html.php?did=2291. Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015). Anti-cancer chalcones: Structural and molecular target perspectives. European journal of medicinal chemistry, 98, 69- 114. 2. Mahapatra, D. K., Bharti, S. K., & Asati, V. (2015). Chalcone scaffolds as anti-infective agents: Structural and molecular target perspectives. European journal of medicinal chemistry, 101, 496-524. 3. Mahapatra, D. K., Asati, V., & Bharti, S. K. (2015). Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives. European journal of medicinal chemistry, 92, 839-865. 4. Mahapatra, D. K., & Bharti, S. K. (2016). Therapeutic potential of chalcones as cardiovascular agents. Life sciences, 148, 154- 172. 5. Mahapatra, D. K., Bharti, S. K., & Asati, V. (2017). Chalcone derivatives: Anti-inflammatory potential and molecular targets perspectives. Current topics in medicinal chemistry, 17(28), 3146-3169. 6. Mahapatra, D. K., Bharti, S. K., Asati, V., & Singh, S. K. (2019). Perspectives of medicinally privileged chalcone based metal coordination compounds for biomedical applications. European journal of medicinal chemistry, 174, 142-58. 7. Mahapatra, D. K., Asati, V., & Bharti, S. K. (2019). An updated patent review of therapeutic applications of chalcone derivatives (2014-present). Expert opinion on therapeutic patents, 29(5), 385-406. 8. Ferrara, N., Gerber, H. P., & LeCouter, J. (2003). The biology of VEGF and its receptors. Nature medicine, 9(6), 669. 9. Ferrara, N. (2002). VEGF and the quest for tumour angiogenesis factors. Nature Reviews Cancer, 2(10), 795. 10. McCOLL, B. K., Stacker, S. A., & Achen, M. G. (2004). Molecular regulation of the VEGF family–inducers of angiogenesis and lymphangiogenesis. Apmis, 112(7?8), 463-480. 11. Przybylski, M. (2009). A review of the current research on the role of bFGF and VEGF in angiogenesis. Journal of wound care, 18(12), 516-519. 12. Nagy, J. A., Dvorak, A. M., & Dvorak, H. F. (2007). VEGF-A and the induction of pathological angiogenesis. Annu. Rev. Pathol. Mech. Dis., 2, 251-275. 13. Baka, S., Clamp, A. R., & Jayson, G. C. (2006). A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert opinion on therapeutic targets, 10(6), 867- 876. 14. Ferrara, N., & Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature, 438(7070), 967. 15. Sawamiphak, S., Seidel, S., Essmann, C. L., Wilkinson, G. A., Pitulescu, M. E., Acker, T., & Acker-Palmer, A. (2010). Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature, 465(7297), 487. 16. D’Haene, N., Sauvage, S., Maris, C., Adanja, I., Le Mercier, M., Decaestecker, C., Baum, L., & Salmon, I. (2013). VEGFR1 and VEGFR2 involvement in extracellular galectin-1-and galectin- 3-induced angiogenesis. PloS one, 8(6), e67029. 17. Li, J., Huang, S., Armstrong, E. A., Fowler, J. F., & Harari, P. M. (2005). Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. International Journal of Radiation Oncology Biology Physics, 62(5), 1477-1485. 18. Shibuya, M. (2006). Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis, 9(4), 225-230. 19. Rizvi, S. U. F., Siddiqui, H. L., Nisar, M., Khan, N., & Khan, I. (2012). Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase. Bioorganic & medicinal chemistry letters, 22(2), 942- 944. 20. Wang, Z., Wang, N., Han, S., Wang, D., Mo, S., Yu, L., Huang, H., Tsui, K., Shen, J., & Chen, J. (2013). Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PloS one, 8(7), e68566. 21. Sun Yat-Sen Cancer Center, South China Institute of Botany, Chinese Academy of Sciences assignee. Use of 2’,4’-dihydroxy- 6’-methoxy-3’,5’-dimethylchalcone for preparing anticancer medicine. Patent CN1454895 A. 12 Nov 2003.